Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NexgenRxTSXV:NXG 50 FCF Margin % is -12.61% as of Jun. 2026. GuruFocus rates TSXV:NXG with a GF Score™ of 50/100 and a GF Value™ of C$0.33 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 671 Healthcare Providers & Services companies, NexgenRx ranks better than 88.23% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NexgenRx's Free Cash Flow for the
three
months ended in Jun. 2026 was C$-0.65 Mil. NexgenRx's Revenue for the
three
months ended in Jun. 2026 was C$5.16 Mil. Therefore, NexgenRx's FCF Margin % for the quarter that ended in Jun. 2026 was -12.61%.
The historical rank and industry rank for NexgenRx's FCF Margin % or its related term are showing as below:
TSXV:NXG'
s FCF Margin % Range Over the Past 10 Years
Min: -12.69 Med: 4.71 Max: 25.83
Current: 15.78
During the past 13 years, the highest FCF Margin % of NexgenRx was 25.83%. The lowest was -12.69%. And the median was 4.71%.
TSXV:NXG's FCF Margin % is ranked better than 88.23% of 671
companies
in the Healthcare Providers & Services industry
Industry Median: 3.06
vs TSXV:NXG: 15.78
The historical data trend for NexgenRx's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:NXG vs VEEV, BTSG, TEM: FCF Margin % Comparison
For the Health Information Services subindustry, NexgenRx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexgenRx FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's FCF Margin % distribution charts can be found below:
* The bar in red indicates where NexgenRx's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexgenRx (TSXV:NXG) has a FCF Margin % of -12.61% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on NexgenRx and its competitors. According to the industry distribution chart, NexgenRx ranks #79 out of 671 companies in the Healthcare Providers & Services industry, placing it in the top 11.8%.
Is NexgenRx's FCF Margin % too high?
NexgenRx's current FCF Margin % is -12.61%. Based on the distribution chart, NexgenRx ranks #79 out of 671 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NexgenRx has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's FCF Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #79 out of 671 companies for FCF Margin %. This places NexgenRx in the top 12% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 3.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.06, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on NexgenRx and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current FCF Margin % is -12.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (TSXV:NXG) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.33, compared to a current price of C$0.61 — trading 84.8% above its estimated fair value. The current FCF Margin % is -12.61%. NexgenRx's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For NexgenRx (TSXV:NXG), the current FCF Margin % is -12.61% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (TSXV:NXG) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of C$0.61 is trading 84.8% above its estimated GF Value™ of C$0.33.
GuruFocus considers NexgenRx to be Significantly Overvalued.
Key valuation signals for TSXV:NXG:
FCF Margin %: -12.61%
GF Value™: C$0.33 vs. price of C$0.61 (84.8% above fair value)
No single metric tells the full story. See the TSXV:NXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
50GF Score
Get the complete analysis for TSXV:NXG
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NXG has been successfully added to your 
